 |
The Roadmap to Informed Healthcare
|
|
|
Click below to receive our CrossRoads newsletter.
|  |
|
|
Greetings!
Welcome to the October issue of CrossRoads, a regular newsletter from Pharmacist Partners.
|
October is Breast Cancer Awareness Month
| |
The incidence of breast cancer is highest in more developed countries and lowest in less developed countries. Consequently, the United States has the most cases of breast cancer in the world. It is the most common type of cancer among American women after skin cancer, and is the second leading cause of cancer death in women after lung cancer. Studies report that breast cancer patients with diabetes were nearly 50% more likely to die than those who didn't have diabetes. There are very promising new treatments such as Roche's Perjeta: the first cancer drug to treat patients before surgery, and the first to qualify for FDA approval based upon tumor shrink age rather than survival data.
Did you know:
- The first operation to use anesthesia was a breast cancer surgery.
- In 1975, the only treatment considered for breast cancer was mastectomy, and the 5-year survival rate was 75%. With better screening techniques, an understanding of breast cancer subtypes, and a plethora of new treatment options, today's 5-year survival rate is 90% and improving.
- The left breast is statistically more prone to developing cancer than the right breast. Scientists are unsure why.
- The American Journal of Clinical Nutrition reports a higher risk of breast cancer in women who take multivitamins.
- Research has found that pomegranates may help prevent breast cancer. Chemicals called ellagitannins block the production of estrogen, which can fuel some types of breast cancer.
|
Pharmacist Partners As An Alternative to MSL's
| |
THE CKO™ Advantage
Globally speaking the industry is shifting from pure marketing campaigns toward targeted clinical consultations for specialty products. Our pharmacist partners represent a key value-add to our clients as they benefit from having knowledge of brand strategy while maintaining scientific objectivity. Therefore, we embody similar benefits afforded by an MSL or MSL contract service, however,we possess distinct advantages.
|
Pharmacist PartnersŪ CKO
|
Medical Science Liaisons
| |
Clinical Credibility with advanced degrees - PharmD, R.Ph.
| 
| √
| |
Established Relationships with Pharmacists & Providers
|
|
Limited to KOL's
| |
Drug,Disease & Category Expertise
|
| √
| |
Flexible territory allocation & redeployment
|
|
NA
| |
Complement Sales & Marketing Efforts
|
|
Limited to Medical Affairs
| |
Trained in Medication Therapy Management (MTM)
|
|
Not required
| |
Non-Commissioned Consultants
|
| √
|
|
Trendsetters
| |
"In today's world, innovation is the new leadership", says Kevin Cashman writing for Forbes. "But as much as we laud the value-creating potential of innovation, we rarely ask ourselves: Where does innovation come from? Where does it begin? What does it look like? How does it become embodied in the people and the culture of organizations?"Several characteristics continually emerge as keys for fostering innovation at all levels. Each month we will profile a different trendsetter. Meet our favorite Pharm-innovator, Matthew Emmens (former CEO of Shire and Vertex). He began his career as a security guard at Fairleigh Dickinson University, which led him to  | | Matt Emmens |
an entry level sales position at Merck. Emmens' book, Zenobia, The Curious Book of Business: A Tale of Triumph Over Yes-Men, Cynics, Hedgers, and Other Corporate Killjoys is a must read, particularly for those who don't believe in cartoons or fairy-tales. The book reminds us how teamwork, courage and vision are integral drivers of long-term success."It's about getting a group of people together, and developing a vision that seems impossible. Then achieving it. It's not about proving anything. It's about involving those people in an undertaking that they'll remember their whole life," Emmens said in a 2010 interview with Luke Timmerman. |
|
|
|
Our guiding principle is in line with our clients - to improve patient health.
I've often heard, "we are all affected by cancer, either personally or through certain degrees of separation". It's true. I lost my Aunt to cancer. And to a less severe extent we are all only one degree removed from someone afflicted by a health condition. Statistics indicate an increasing number of such conditions are chronic and therefore require frequently administered drug therapy. For example, obesity affects the majority of Americans and heart disease remains the leading cause of death, while diabetes is increasing year over year and will soon match or surpass the incidence of these other aforementioned conditions. If cancer is the condition requiring therapeutic attention then the oncologists need to be adequately informed of the latest treatment methods and available medicines. Evidently only 19% of oncologists surveyed in a recent CMI study permitted interaction with sales reps.
If we raise the clinical level of the interaction focusing on the science, I believe we can break down the barriers imposed by dis-enfranchised specialists, namely oncologists. Our pharmacist partners are equipped to do just that. They are licensed, highly educated, and proactive in their role as advocates for increased medication literacy amongst practitioners and patients. If this level of access continues to become more restrictive the cancer patient invariably suffers as do the many people removed along the degrees of separation.
Sincerely,
David
David Perry, CEO
Pharmacist Partners LLC
1-855-742-7611 |
|
|
|
|
